FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069430564> ?p ?o ?g. }

• W2069430564 endingPage "1267" @default.
• W2069430564 startingPage "1267" @default.
• W2069430564 abstract "Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation Antonio Ieni,1 Valeria Barresi,1 Rosario Caltabiano,2 Anna Maria Cascone,3 Rachele Del Sordo,4 Daniela Cabibi,5 Pio Zeppa,3 Salvatore Lanzafame,2 Angelo Sidoni,4 Vito Franco,5 Giovanni Tuccari1 1Department of Human Pathology Gaetano Barresi, Section of Anatomic Pathology, University of Messina, Messina, 2Department GF Ingrassia, Section of Anatomic Pathology, University of Catania, Catania, 3Department of Medicine and Surgery, University of Salerno, Salerno, 4Institute of Pathologic Anatomy and Histology, Division of Cancer Research, University of Perugia, Perugia, 5Department of Human Pathology, Section of Anatomic Pathology, University of Palermo, Palermo, Italy Background: Human epidermal growth factor receptor 2 (HER2) is considered to be a therapeutic and prognostic marker in the management of breast carcinoma (BC), although discordance rates between primary and metastatic or locally recurrent lesions have been reported. Methods: One hundred and forty-eight paraffin-embedded BC tissues from patients of mean age 59.27 (33–96) years and corresponding synchronous lymph node metastases were collected and retrospectively studied using immunohistochemistry and fluorescence in situ hybridization to evaluate HER2 status. Fleiss-Cohen weighted k statistics were used to assess the concordance rate between HER2 status of the primary BC and the synchronous metastatic lesions. Results: The overall concordance rate for HER2 was 95.28%. Eighty-nine cases were concordantly HER2-negative in primary BC and nodal metastases, and 52 cases were HER2-positive in both primary and metastatic tumors. Changes in HER2 status between primary BC and corresponding synchronous metastases were observed in seven (4.72%) cases. Three of the discordant cases were HER2-negative in the primary tumor and HER2-positive in the metastases, while four cases were HER2-positive in the primary BC and HER2-negative in the metastases. No significant correlations were identified between HER2 status and expression of hormone receptors, growth fraction (Ki-67), or other histopathological parameters (pT, pN, grade). Conclusion: Simultaneous determination of HER2 in BC and corresponding metastatic lymph nodes is not mandatory, but may strongly influence the therapeutic management. It was demonstrated that loss of HER2 amplification results in worse post-relapse survival and overall survival in BC patients and, on the other hand, a gain in HER2 expression in metastatic lymph nodes of BC may allow the possibility of a targeted treatment. Thus, our opinion is that significant prognostic information may be obtained by simultaneous assessment of HER2 status in both primary and synchronous metastatic BC. Keywords: human epidermal growth factor receptor 2, breast cancer, synchronous lymph nodes, metastases, prognosis" @default.
• W2069430564 created "2016-06-24" @default.
• W2069430564 creator A5010187100 @default.
• W2069430564 creator A5020130612 @default.
• W2069430564 creator A5022918312 @default.
• W2069430564 creator A5038858481 @default.
• W2069430564 creator A5042484828 @default.
• W2069430564 creator A5052518395 @default.
• W2069430564 creator A5057940142 @default.
• W2069430564 creator A5060024240 @default.
• W2069430564 creator A5061835885 @default.
• W2069430564 creator A5087427494 @default.
• W2069430564 creator A5090620646 @default.
• W2069430564 date "2014-07-01" @default.
• W2069430564 modified "2023-10-01" @default.
• W2069430564 title "Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation" @default.
• W2069430564 cites W101849968 @default.
• W2069430564 cites W1626477266 @default.
• W2069430564 cites W1977152516 @default.
• W2069430564 cites W1999042449 @default.
• W2069430564 cites W2023915585 @default.
• W2069430564 cites W2024032315 @default.
• W2069430564 cites W2040354648 @default.
• W2069430564 cites W2047207396 @default.
• W2069430564 cites W2051548309 @default.
• W2069430564 cites W2060368924 @default.
• W2069430564 cites W2065803223 @default.
• W2069430564 cites W2072368645 @default.
• W2069430564 cites W2072557285 @default.
• W2069430564 cites W2073427945 @default.
• W2069430564 cites W2098719877 @default.
• W2069430564 cites W2099117820 @default.
• W2069430564 cites W2099630695 @default.
• W2069430564 cites W2113233663 @default.
• W2069430564 cites W2114234969 @default.
• W2069430564 cites W2119065193 @default.
• W2069430564 cites W2125785648 @default.
• W2069430564 cites W2126324838 @default.
• W2069430564 cites W2130828084 @default.
• W2069430564 cites W2144396863 @default.
• W2069430564 cites W2152940687 @default.
• W2069430564 cites W2153514438 @default.
• W2069430564 cites W2154671238 @default.
• W2069430564 cites W2157434805 @default.
• W2069430564 cites W2163873687 @default.
• W2069430564 cites W2165999332 @default.
• W2069430564 cites W2168424827 @default.
• W2069430564 cites W2314556209 @default.
• W2069430564 doi "https://doi.org/10.2147/ott.s65294" @default.
• W2069430564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4103929" @default.
• W2069430564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25050068" @default.
• W2069430564 hasPublicationYear "2014" @default.
• W2069430564 type Work @default.
• W2069430564 sameAs 2069430564 @default.
• W2069430564 citedByCount "23" @default.
• W2069430564 countsByYear W20694305642014 @default.
• W2069430564 countsByYear W20694305642015 @default.
• W2069430564 countsByYear W20694305642016 @default.
• W2069430564 countsByYear W20694305642017 @default.
• W2069430564 countsByYear W20694305642018 @default.
• W2069430564 countsByYear W20694305642019 @default.
• W2069430564 countsByYear W20694305642020 @default.
• W2069430564 countsByYear W20694305642021 @default.
• W2069430564 countsByYear W20694305642022 @default.
• W2069430564 countsByYear W20694305642023 @default.
• W2069430564 crossrefType "journal-article" @default.
• W2069430564 hasAuthorship W2069430564A5010187100 @default.
• W2069430564 hasAuthorship W2069430564A5020130612 @default.
• W2069430564 hasAuthorship W2069430564A5022918312 @default.
• W2069430564 hasAuthorship W2069430564A5038858481 @default.
• W2069430564 hasAuthorship W2069430564A5042484828 @default.
• W2069430564 hasAuthorship W2069430564A5052518395 @default.
• W2069430564 hasAuthorship W2069430564A5057940142 @default.
• W2069430564 hasAuthorship W2069430564A5060024240 @default.
• W2069430564 hasAuthorship W2069430564A5061835885 @default.
• W2069430564 hasAuthorship W2069430564A5087427494 @default.
• W2069430564 hasAuthorship W2069430564A5090620646 @default.
• W2069430564 hasBestOaLocation W20694305641 @default.
• W2069430564 hasConcept C121608353 @default.
• W2069430564 hasConcept C126322002 @default.
• W2069430564 hasConcept C142724271 @default.
• W2069430564 hasConcept C143998085 @default.
• W2069430564 hasConcept C160798450 @default.
• W2069430564 hasConcept C167135981 @default.
• W2069430564 hasConcept C204232928 @default.
• W2069430564 hasConcept C2777649267 @default.
• W2069430564 hasConcept C2780849966 @default.
• W2069430564 hasConcept C530470458 @default.
• W2069430564 hasConcept C71924100 @default.
• W2069430564 hasConceptScore W2069430564C121608353 @default.
• W2069430564 hasConceptScore W2069430564C126322002 @default.
• W2069430564 hasConceptScore W2069430564C142724271 @default.
• W2069430564 hasConceptScore W2069430564C143998085 @default.
• W2069430564 hasConceptScore W2069430564C160798450 @default.
• W2069430564 hasConceptScore W2069430564C167135981 @default.
• W2069430564 hasConceptScore W2069430564C204232928 @default.
• W2069430564 hasConceptScore W2069430564C2777649267 @default.
• W2069430564 hasConceptScore W2069430564C2780849966 @default.

• next